Saturday 17 October 2026 Export OFIX’s income statement to Excel — free account

ORTHOFIX MEDICAL INC.

ORTHOFIX MEDICAL INC.’s revenue for fiscal 2025 (year ended December 2025) was $822.3 million, up 2.85% from fiscal 2024. In the quarter to June 2026, revenue grew 3.85%, EPS fell 8.33%, free cash flow fell 516.6% and total debt rose 34.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

9.38 0.21 −2.19%

Follow OFIX

Alert me

Market cap: $390.6M
P/E: 0.0×
Fwd P/E: −8.5×
Dividend yield: —
F-score: 5/9
Altman Z: 1.29
Beneish M: −3.19
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 6.82

Total sells 6.60

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	1	—	2	—	—	—	1	—
Sell	—	—	2	—	8	1	1	1	—	2	1	1

Insider Ownership 1.63%

Capital & Financial Ratios $m

Market Cap 390.63

Revenue 833.19

Net Income (61.72)

Free Cash Flow (27.82)

Net Debt 130.09

Current Ratio 2.84

Debt/Equity 0.55

P/E ratio 0.00

Fwd P/E (8.47)

P/S ratio 0.46

P/B ratio 0.89

Past 5Y EPS Growth —

This Y EPS Growth 49.57%

Next Y EPS Growth 19.57%

Next Y revenue growth 3.49%

Next 5Y EPS Growth 35.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.40%

10-year low 10-year high

P/B against its own 10 years 7.96%

10-year low 10-year high

EV/Sales against its own 10 years 2.54%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	38	86	85	104
Receivables	128	135	136	136
Inventory	222	189	172	184
Other	—	—	—	—
	420	433	417	446

	2023	2024	2025	Q'26
Payables	58	49	58	64
ST’ Debt	1	—	—	—
Other	105	119	111	93
	165	169	170	157

Compound Annual Growth %

	10y	5y	3y
Sales	7.57%	15.13%	21.30%
Cash Flow	(2.65%)	(14.80%)	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.48%	4.75%	10.14%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	197	211	—	—	—
’25	194	203	206	220	822
’24	189	199	197	216	799
’23	175	187	184	200	747
’22	106	118	114	122	461
’21	106	121	112	125	464
’20	105	73	111	118	407

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(6)	—	—	—
’25	(18)	12	12	28	33
’24	(19)	9	12	24	26
’23	(34)	(6)	0	(7)	(46)
’22	(8)	(5)	(1)	2	(12)
’21	2	(2)	6	12	18
’20	12	18	22	22	74

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(28)	(19)	—	—	—
’25	(25)	5	2	17	(1)
’24	(29)	(1)	6	15	(9)
’23	(46)	(18)	(23)	(22)	(108)
’22	(14)	(13)	(6)	(4)	(35)
’21	(3)	(8)	3	4	(1)
’20	6	13	19	10	50

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.52)	(0.39)	—	—	—
’25	(1.35)	(0.36)	(0.57)	(0.06)	(2.33)
’24	(0.95)	(0.88)	(0.71)	(0.75)	(3.30)
’23	(1.71)	(1.07)	(0.77)	(0.59)	(4.12)
’22	(0.22)	0.12	(0.53)	(0.35)	(0.98)
’21	(0.30)	0.12	(0.11)	(1.65)	(1.95)
’20	1.32	(0.96)	0.24	(0.48)	0.13

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	32.51	33.51	48.00	39.75	22.11	28.65	13.76	9.57	12.08	10.24	Analyst estimates 2026–2028 Powerpack
	High	48.25	56.53	63.57	74.44	47.91	48.50	36.13	23.19	20.73	20.48
People
People	Employees	938	858	954	1,055	1,036	1,087	1,092	1,634	1,616	1,605
	Revenue/emp, $m	0.44	0.51	0.47	0.44	0.39	0.43	0.42	0.46	0.49	0.51
Income, $m
Income, $m	Revenue	410	434	453	460	407	464	461	747	799	822
	Gross margin, %	78.56	78.55	78.67	78.13	74.94	75.26	73.18	65.13	68.28	68.83
	EBT	19	36	23	(27)	0	(13)	(18)	(149)	(124)	(91)
	EBT margin, %	4.64	8.39	5.05	(5.88)	(0.09)	(2.91)	(3.84)	(19.91)	(15.49)	(11.04)
	Net income	3	6	14	(28)	3	(38)	(20)	(151)	(126)	(92)
	Depreciation	22	22	20	28	34	45	32	97	88	83
Per share, $
Per share, $	Revenue	22.59	23.95	24.50	24.33	21.10	23.59	22.97	20.33	20.97	20.76
	Earnings	0.17	0.34	0.73	(1.51)	0.13	(1.95)	(0.98)	(4.12)	(3.30)	(2.33)
	Cash flow	3.26	2.15	2.70	1.69	3.85	0.94	(0.58)	(1.25)	0.68	0.84
	Capex	(1.01)	(0.91)	(0.90)	(1.09)	(1.26)	(0.99)	(1.15)	(1.69)	(0.91)	(0.87)
	Free cash flow	2.25	1.24	1.80	0.61	2.59	(0.06)	(1.73)	(2.94)	(0.24)	(0.03)
	Book value	14.52	16.37	18.14	17.33	18.52	17.11	16.80	16.30	13.19	11.36
	Shares, m	18	18	18	19	19	20	20	37	38	40
Valuation, ×
Valuation, ×	P/E	209.00	160.41	71.90	0.00	330.62	0.00	0.00	0.00	0.00	0.00
	P/S	1.57	2.28	2.14	1.90	2.04	1.32	0.93	0.65	0.83	0.73
	P/B	2.45	3.33	2.89	2.66	2.32	1.82	1.27	0.81	1.32	1.33
	EV/Sales	1.49	2.14	2.03	1.79	1.86	1.18	0.87	0.75	0.95	0.85
	EV/FCF	15.72	49.20	29.11	82.69	15.65	(187.64)	(10.83)	(5.06)	(66.79)	(193.86)
Cash, $m
Cash, $m	Operating cash flow	59	39	50	32	74	18	(12)	(46)	26	33
	Capex	(18)	(16)	(17)	(21)	(24)	(20)	(23)	(62)	(35)	(35)
	Free cash flow	41	22	33	12	50	(1)	(35)	(108)	(9)	(1)
Balance, $m
Balance, $m	Working capital	111	172	159	176	166	164	172	255	265	246
	Total debt	—	—	—	23	25	24	22	113	175	174
	Net debt	(54)	(81)	(72)	(48)	(72)	(64)	(29)	75	89	89
	Shareholders’ equity	263	297	335	328	357	337	337	599	503	450
Returns, %
Returns, %	ROA	0.79	1.60	3.17	(5.92)	0.49	(7.66)	(4.22)	(21.88)	(13.86)	(10.57)
	ROIC	6.28	11.84	7.15	(4.19)	(1.37)	(1.90)	(2.70)	(12.90)	(8.93)	(9.44)
	ROE	1.10	2.22	4.37	(8.59)	0.74	(11.06)	(5.86)	(32.36)	(22.87)	(19.34)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BWAY Brainsway Ltd. Sponsored ADR	$475.8M	24.8×	— (loss-making)	+35.43% (above 0%: growing)	+40.00% (above 0%: growing)	−51.68% (below 0%: shrinking)	74.62%	13.98%	Compare
CERS Cerus Corporation	$455.5M	— (loss-making)	— (loss-making)	+5.28% (above 0%: growing)	n/m	−20.90% (below 0%: shrinking)	55.91%	(2.94%)	Compare
NPCE NeuroPace, Inc.	$438.7M	— (loss-making)	— (loss-making)	+17.05% (above 0%: growing)	n/m	−78.70% (below 0%: shrinking)	82.83%	(22.53%)	Compare
SENS Senseonics Holdings, Inc.	$435.2M	— (loss-making)	— (loss-making)	+117.82% (above 0%: growing)	n/m	−223.24% (below 0%: shrinking)	59.10%	(248.48%)	Compare
OFIX ORTHOFIX MEDICAL INC.	$390.6M	— (loss-making)	— (loss-making)	+3.85% (above 0%: growing)	n/m	−516.58% (below 0%: shrinking)	70.97%	(3.86%)
SI Shoulder Innovations, Inc.	$382.4M	— (loss-making)	— (loss-making)	+55.95% (above 0%: growing)	n/m	−52.42% (below 0%: shrinking)	78.26%	(58.43%)	Compare
VMD Viemed Healthcare, Inc.	$371.4M	24.9×	21.9×	+23.85% (above 0%: growing)	−12.50% (below 0%: shrinking)	−18.15% (below 0%: shrinking)	57.68%	6.39%	Compare
CV CapsoVision, Inc.	$343.2M	2.1×	— (loss-making)	+9.89% (above 0%: growing)	n/m	−84.44% (below 0%: shrinking)	51.36%	(208.07%)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)	Compare
Median of peers	$408.8M	24.8×	—	+20.84%	—	−52.05%	66.86%	(25.48%)

All 149 Medical Devices stocks →

ORTHOFIX MEDICAL INC. (OFIX) key facts

Concern: ORTHOFIX MEDICAL INC. reported a net loss of $92.2 million, or a loss of $2.33 per share, for fiscal 2025.
Strength: ORTHOFIX MEDICAL INC.’s revenue for fiscal 2025 (year ended December 2025) was $822.3 million, up 2.85% from fiscal 2024.
ORTHOFIX MEDICAL INC. (OFIX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OFIX traded at $9.38, a market capitalization of $390.6 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
Return on equity was −19.3% and debt-to-equity 0.55.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.29 (distress zone) for fiscal 2025.